Quantro Therapeutics Funding Round

11/4/2026

Debt

Unknown

Undisclosed

The company intends to use the funds to support the development of ASCEND, its AI-driven medicinal chemistry platform, accelerating its drug discovery pipeline and establishing versatile workflows for the optimization of small molecule modulators and degraders.

Private & Independent

Biopharmaceutical

Helmut-Qualtinger-Gasse 2
Vienna, 1030
Austria

QUANTRO combines time-resolved transcriptomics with functional biology and medicinal chemistry to build first-in-class programmes. Our Mission: Build medicines against transcriptional targets that conventional drug discovery cannot adequately address. QUANTRO is pioneering transcriptomic drug discovery; After successful implementation of our drug discovery platform, QUANTRO is now creating innovative, first-in-class R&D portfolios, internally and in strategic pharma partnerships. Starting in 2019 with SLAMseq®, discovered by QUANTRO co-founders Stefan Ameres and Johannes Zuber, QUANTRO was founded as an IMBA and IMP spin-out. Since then, the company has successfully translated the originating science into a high-performance industrial drug discovery platform.